FILTER

FILTERED INTERVIEW RESULTS

Carlos De Lion Neto

SOUTHERN CONE PRESIDENT, ARKEMA
"As the scale of sustainable products increases, it becomes easier to introduce these materials into both mature markets and developing markets."

Jan Krueder and Matthias Vorbeck

JK: CEO, QUÍMICA ANASTACIO AND MV: GENERAL DIRECTOR, ANASTACIO OVERSEAS
"Our leadership in Brazilian distribution demands competitive pricing strategies, robust sourcing capabilities and negotiating locally for efficient logistic solutions."

Carla Wilson

GENERAL MANAGER, BHP BRASIL
"Our top priority in Brazil remains ensuring the full and fair reparation of those affected by the Samarco dam failure."

Ana Sanches

CEO, ANGLO AMERICAN BRASIL
"Mining is one of the Brazilian economy's three main sectors and one with the greatest potential for growth in the next decade."

Paulo Misk

COO, LITHIUM IONIC
"The unique geological conditions in the Jequitinhonha Valley favor spodumene crystallization, making it one of the best areas globally for lithium extraction."

Luis Azevedo

CEO, BRAVO MINING
"Carajás represents a frontier mining region where significant deposits are still viable, and we have already identified considerable mineralization, hinting at potentially groundbreaking discoveries."

Rodrigo Couto

PRESIDENT LATAM, HEXAGON
"We aim to be technology enablers by consolidating multiple operational solutions into a single interface."

Rodrigo Vilela

CEO, SAMARCO
"In 2025, we aim to produce approximately 15 million t of pellets, which positions us as one of the largest exporters globally, as we were in the past."

Rodrigo Nunes

COO, HOCHSCHILD MINING
"Our positive experience in Brazil has encouraged us to continue growing in the country."

Bernardo Viana

PARTNER, GE21 CONSULTORIA MINERAL
"Last year we saw significant project growth, particularly with rare earth elements."

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS